6-[3-[(4-chlorophenyl)methyl-methylamino]-2-hydroxypropoxy]-1H-quinolin-2-one | 128667-35-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-[3-[(4-chlorophenyl)methyl-methylamino]-2-hydroxypropoxy]-1H-quinolin-2-one
• CAS: 128667-35-6
• 化学式: C₂₀H₂₁ClN₂O₃
• 分子量: 372.851
• InChiKey: OPBXODDPFVCESI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-(2,3-epoxypropoxy)-2(1H)-quinolinone 、 N-甲基-4-氯苄胺 以 甲醇 为溶剂， 反应 3.0h， 生成 6-[3-[(4-chlorophenyl)methyl-methylamino]-2-hydroxypropoxy]-1H-quinolin-2-one
  参考文献：
  名称：

  Novel positive inotropic agents: synthesis and biological activities of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinone derivatives

  摘要：

  A series of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinones has been synthesized and evaluated for positive inotropic activity on the canine heart. Some of these derivatives have a potent activity with none or negative chronotropic effect in isolated, blood-perfused dog heart preparations. They also display a high selectivity for positive inotropic effect over chronotropic and vasodilatory effects in anesthetized dogs. (+/-)-6-[2-Hydroxy-3-[(3-methoxybenzyl)amino]propoxy]-2(1H)-quinolinone (39) and (+/-)-6-[3-(3,4-dimethoxybenzyl)amino]-2-hydroxypropoxy]-2(1H)-quinolinone (40) were further investigated in conscious dogs. After iv administration, they did not affect heart rate or mean blood pressure at the dose producing a 50% increase in the peak of the first derivative of the left ventricular pressure. The compounds (39,OPC-18750, and 40,OPC-18790) are the most promising agents with desirable biological activities, and now are currently undergoing clinical evaluation.

  DOI：

  10.1021/jm00098a003

文献信息

• Cardiotonics
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0355583A2

  公开（公告）日：1990-02-28

  Agent for prophylaxis and treatment of heart diseases using a carbostyril derivative of formula: wherein R1 is H or CN, and R2 and R3 are each H, alkyl optionally substituted by OH, cycloalkyl, alkenyl, phenyl, phenylalkyl having optionally substituents of alkoxyalkoxy, halogen, alkoxy, N02, alkyl, CN, alkylthio or alkylsulfinyl on phenyl ring and having optionally OH-substituent on alkyl moiety, phenylsulfonylalkyl having optionally alkoxy substituent on phenyl ring, phenylthioalkyl, phenylsulfinylalkyl having optionally substituents of halogen or alkoxy on phenyl ring, phenoxyalkyl having optionally substituents of halogen or alkoxy on phenyl ring, pyridylalkyl having optionally substituents of halogen or alkoxy on pyridine ring, thienylalkyl, benzoylalkyl, anilinothiocarbonyl, benzoyl, pyridyl, phenylalkenyl, or group of -A-NR4R5 (R4 and R5, are each alkyl or phenyl having optionally substituents of halogen or alkoxy on phenyl ring, and A is alkylene which may be interrupted with 0), and a salt thereof, and novel carbostyril derivatives, and pharmaceutical composition for prophylaxis and treatment of heart diseases containing said novel carbostyril derivative.

  用于预防和治疗心脏病的制剂，使用式中的羧基吡啶衍生物： 其中 R1 是 H 或 CN，R2 和 R3 分别是 H、任选被 OH 取代的烷基、环烷基、烯基、苯基、苯基环上任选具有烷氧基、卤素、烷氧基、N02、烷基、CN、烷硫基或烷基亚磺酰基的苯基烷基以及烷基上任选具有 OH 取代基的苯基烷基、苯基环上有卤素或烷氧基取代基的苯磺酰烷基、苯硫酰烷基、苯基环上有卤素或烷氧基取代基的苯亚磺酰烷基、苯基环上有卤素或烷氧基取代基的苯氧基烷基、在吡啶环上可选择卤素或烷氧基取代基的吡啶烷基、噻吩烷基、苯甲酰烷基、苯甲硫羰基、苯甲酰基、吡啶基、苯基烯基或-A-NR4R5（R4 和 R5 均为在苯基环上可选择卤素或烷氧基取代基的烷基或苯基）基团、及其盐、新型卡波替林衍生物，以及含有上述新型卡波替林衍生物的预防和治疗心脏病的药物组合物。
• US5053514A
  申请人：——

  公开号：US5053514A

  公开（公告）日：1991-10-01
• US5198448A
  申请人：——

  公开号：US5198448A

  公开（公告）日：1993-03-30
• US5266577A
  申请人：——

  公开号：US5266577A

  公开（公告）日：1993-11-30
• US5385914A
  申请人：——

  公开号：US5385914A

  公开（公告）日：1995-01-31